Obstructive sleep apnoea syndrome (OSAS), due to the collapse of the upper airways, is a common but still underestimated condition. The 'dose-response' type relationship between OSAS and hypertension (HT) has now been clearly proven. There are multiple mechanisms explaining this relationship, the main one being an increase in sympathetic activity during the apnoeas. HT associated with OSAS has several characteristics: high prevalence, diastolic and nocturnal predominance, and frequent non-dipper status. Furthermore, as OSAS is found in the majority of subjects with refractory HT, it should be systematically investigated in this situation. HT associated with OSAS should be tested for by means of a clinical blood pressure (BP) measurement, to which 24-h ambulatory BP monitoring (ABPM) is often added due to the fact that BP anomalies are frequently present at night. HT during OSAS is frequently associated with metabolic anomalies (for example, obesity, dyslipidaemia and insulin resistance), therefore explaining the high prevalence of metabolic syndrome in this population. The reference treatment for OSAS-nasal continuous positive airway pressure (nCPAP)-seems to be able to lower the BP of hypertensive patients, especially if the HT is severe, untreated or refractory. Moreover, the BP response to nCPAP depends on the severity of the OSAS, in particular the scale of the nocturnal desaturations, and on patient tolerance of the treatment. Optimal treatment for HT associated with OSAS has not been evidenced. Antihypertensive drugs do not change the respiratory parameters during OSAS.
Introduction
Obstructive sleep apnoea syndrome (OSAS) is a common condition affecting around 5% of the general population, primarily men. 1 The clinical picture includes four main symptoms: diurnal hypersomnia, frequent nocturnal arousals with nycturia, morning asthenia with or without headache and severe snoring. Factors promoting OSAS are not only obesity, age, smoking and alcohol consumption, but also and above all, anatomic and/or functional anomalies of the upper airway. It is now an acknowledged public health problem, not only due to its high prevalence, but also due to somnolence, [2] [3] [4] cognitive [5] [6] [7] and cardiovascular morbidity [8] [9] [10] particularly hypertension (HT), [11] [12] [13] [14] [15] coronary artery disease, [16] [17] [18] cerebrovascular disease [19] [20] [21] [22] and rhythm/conduction disorders [23] [24] [25] [26] [27] -and finally the mortality 22, [28] [29] [30] [31] [32] [33] that are attributed to it. This causal relationship has been clearly shown for HT, but also for coronary artery disease and cardiac arrhythmias, and seems probable for stroke. However, one of the main problems concerning the link between OSAS and cardiovascular diseases is confounding factors, including obesity and particularly visceral obesity.
When OSAS is suspected, one of the approved questionnaires should be used: the Epworth Sleepiness Scale or the Berlin Questionnaire. 34, 35 Polysomnography is the standard examination for diagnosis of nocturnal respiratory arrest. It simultaneously records sleep, airflow (nasal pressure), respiratory effort (thoracic and abdominal respiratory movements), electroencephalogram and SaO 2 . Respiratory polygraphy without a sleep record is also frequently used in European countries for establishing OSAS diagnosis. Sleep apnoea is said to be obstructive if there is persistent respiratory effort. The number of apnoeas (airflow stops completely) and obstructive hypopnoeas (450% reduction in inspiratory flow or 430% reduction linked to more than 3% desaturation and/or microarousals) lasting more than 10 s per hour of sleep (apnoea-hypopnoea index or AHI) can be calculated. When the sensitive tools described above are used, the threshold of 15 events per hour of recording is usually applied for OSAS diagnosis. 15 The reference treatment for OSAS is nasal continuous positive airway pressure (nCPAP) that not only significantly reduces the number and severity of respiratory events but also the cardiovascular complications, in particular coronary complications. 33 
Acute cardiovascular modifications occurring during OSAS
Patients suffering from OSAS present permanent oscillations in their haemodynamic parameters during the night. Heart rate, blood pressure (BP) and cardiac output vary incessantly due both to the repetition of respiratory events and the rapid changes in alertness (micro-arousals) caused by the ventilatory anomalies. The cardiovascular responses are the result of the integration of four stimuli: hypoxaemia, hypercapnia, changes to pulmonary volume or intrathoracic pressure and micro-arousals ( Figure 1 ).
Blood pressure variations over the night and acute modifications occurring during the apnoeas have been clearly described in apnoeic patients. However, controversy persists with regard to the mechanisms behind these haemodynamic modifications. BP reaches its lowest level at the beginning of the apnoea and then gradually increases before reaching its maximum level a few seconds after breathing resumes on arousal, which also corresponds to the least negative oesophageal pressure and minimal SaO 2 . 36 The habitual fall in BP-of around 10%-that occurs during the night in normal subjects (the dipping phenomenon) is often insufficient or even absent in apnoeic patients. 14, 36, 37 The existence of a non-dipper profile on the 24-h ambulatory BP monitoring (ABPM) should suggest the possibility of OSAS. 38, 39 All of these haemodynamic variations are the result of the action of several stimuli.
The role of hypoxaemia Responses to acute hypoxia are increased in apnoeic patients 40 in whom the level of O 2 desaturation explains over 30% of the BP variation. The desaturation-reoxygenation sequence is a typical pattern coupled with OSAS. This sequence leads to oxidative stress with production of reactive oxygen species. 41 The increased levels of reactive oxygen species contribute to generate adhesion molecules, 42 to activate leucocytes 43 and to produce systemic inflammation. 44 All together, these mechanisms are generating vascular endothelium damage and dysfunction. 45, 46 Although numerous studies have addressed the issue of increased reactive oxygen species production, there are only a limited number of studies addressing the role of antioxidant capacities in OSA patients. Recently, Faure et al. 47 have shown impairment in albumin antioxidant properties that was independent from body mass index (BMI) and only related to OSA severity. Oxidative stress is generating an inflammatory cascade that increases adhesion molecules expression 48 and further activates monocytes and lymphocytes. 49 There is a chemoreflex modulation of peripheral vascular resistance, mediated essentially by vasoconstriction of sympathetic origin. 50 Two studies including a measurement of sympathetic activity by means of microneurography, one carried out overnight in patients suffering from OSAS 51 and the other on arousal during voluntary apnoeas, 52 show that hyperoxia suppresses sympathetic stimulation and BP variations occurring during an apnoea. On the contrary, the BP peak occurring when ventilation resumes is only partially modified by the hyperoxia, indicating that other mechanisms are involved or associated.
The role of hypercapnia Hypercapnia occurring during apnoeas is itself a sympathetic stimulation factor. However, when the sympathetic responses to hypercapnia are explored in apnoeic patients compared with control subjects, these responses are not increased, contrary to hypoxia. 40 On the other hand, in rats exposed to intermittent hypoxia, sympathetic responses to both hypercapnia and hypoxia increased. 53 In any case, the time lag between the appearance of hypercapnia and acidification of the central chemoreceptors was around 20 s, making the contribution of hypercapnia to the HT peak, following ventilatory resumption plausible. 52 The role of negative intrathoracic pressure The interpretation of BP oscillations is complicated by the concomitant fluctuations in heart rate and the systolic ejection volume. The existence of very negative intra-thoracic pressures could alter the mechanical properties of the left ventricle. The sudden restoration of the left ventricle function during normalization of oesophageal pressure could lead to the post-apnoea HT peak. However, this mechanism probably plays a marginal role compared with the effects of micro-arousal.
The role of micro-arousal
The existence of a micro-arousal (even a nonrespiratory micro-arousal) is enough to cause an HT peak during the change to the subject's state of alertness. 36 This has been reported in apnoeic subjects receiving nCPAP treatment with sleep fragmentation caused by an auditory stimulus. This is also true for micro-arousals caused by periodic leg movements. 54 Finally, in normal subjects, the BP peak obtained is proportional to the intensity of the non-respiratory micro-arousal produced. 55 
Genesis of permanent HT
During OSAS, there are acute and subacute cardiovascular responses connected to repeated episodes of intermittent hypoxaemia and pleural depression developed during respiratory efforts to overcome the pharyngeal obstacle (Figure 1 ). The autonomic nervous system plays an essential role in the genesis of the organism's acute and chronic responses, and partly explains the physiopathological mechanisms behind the chronic cardiovascular consequences linked to OSAS, particularly HT. 56 Regarding animal models, it has been evidenced in a canine model that the upper airway obstruction lead to sustained increase in BP, whereas sleep fragmentation produced only acute but not chronic changes in BP. 57, 58 Much more research has been done, particularly in rodents. Starting from the early evidence provided by Fletcher et al. that intermittent hypoxaemia during nighttime results in daytime increase in BP, there have been many reports on intermittent hypoxaemia effects, mainly on the cardiovascular system. 59 
Sympathetic activity
In humans, chronic elevation of adrenergic tone has been shown in apnoeic subjects. The elevation was shown using sympathetic microneurography of the nerves going to the muscles (Figure 2) 60,61 and assays of plasma and urinary catecholamines. [62] [63] [64] This increase in diurnal sympathetic activity could reflect a modification to the activation level or could indicate that the reflex arcs involved in the regulation of adrenergic tone have come into play. It is also probable that the repeated arousals and abnormal respiratory efforts could contribute to this chronic increase in adrenergic tone. 65 Elevated sympathetic activity causes an increase in peripheral arterial resistance, explaining the predominantly diastolic nature of the HT found in OSAS. Furthermore, it has been shown that apnoeic patients develop excessive cardiovascular sensitivity to sympathetic stimulation due to changes to the endothelial response.
Endothelial dysfunction
During OSAS, there is a change to endothelial function that is independent of obesity and other risk factors for atherosclerosis such as dyslipidaemia, diabetes and smoking. 66 This anomaly is enhanced by the sympathetic activation, systemic inflammation, oxidative stress and increased BP that are often found in apnoeic patients. It can be investigated using various methods including the endothelium-dependent vasodilation analysis used by Kato et al. 66 The endothelial dysfunction of OSAS partly explains the high BP levels recorded in this pathology, as it causes decreased vasodilation and vasoconstriction, essentially due to the inhibition of NO production. 
Inflammation and oxidative stress
Obstructive sleep apnoea syndrome directly affects the vascular endothelium by promoting inflammation and oxidative stress while decreasing NO availability and repair capacity. 67 Shamsuzzaman et al. 68 have shown that apnoeic patients presented systemic inflammation, as evidenced by the increased levels of high-sensitivity C-reactive protein.
Circulating levels of interleukin 6 and tumour necrosis factor-a-two other markers of inflammation-are also increased during OSAS. 69 This inflammation, which is essentially secondary to episodes of hypoxaemia, seems to be associated with an increased risk of developing HT, probably due to the induction of endothelial dysfunction. 70 Oxidative stress is increased during OSAS, particularly because of the phenomenon of hypoxaemia/ reoxygenation. 48 This can partly explain the BP increase in apnoeic patients. Indeed, oxidative stress can cause vasoconstriction by various mechanisms, including the activation of angiotensin II and thromboxane receptors, blockade of NO synthase and increased generation of endothelin-1.
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Renin-angiotensin-aldosterone system An increase in plasma aldosterone levels has been found in patients suffering from OSAS. 72 This hyperaldosteronism is the consequence of the activation of the renin-angiotensin-aldosterone system due to the sympathetic hyperactivity and the abdominal obesity that is often present. 73 Indeed, aldosterone secretion is even greater when there is excess visceral fat. This last mechanism appears to be independent of plasma renin activity. 74 
Metabolic dysfunction
It has now been clearly shown that being overweight or obese encourages the development of HT. Indeed, overweight subjects have a risk of developing HT that is three times higher than the risk run by subjects of normal weight. 75 This is particularly true in obese apnoeic subjects as these two situations (that is, obesity and OSAS) increase sympathetic activity, and therefore BP. The parameters involved are not all known, but aside from sympathetic hyperactivity, leptin (adipocyte-derived hormone) appears to play an important role. Indeed, OSAS is associated with resistance to the metabolic effects of leptin, which seems to be involved in the development of sustained HT. 76, 77 Similarly, the hyperinsulinism that is often present in apnoeic subjects, especially when they are overweight, contributes to OSAS-induced HT as it promotes peripheral vasodilation impairment, endothelial dysfunction, sympathetic hyperactivity and an increase in the renal reabsorption of sodium. 78 
Endothelin system
The endothelin system is involved in the genesis of HT during OSAS. Thus, it has been shown in animals as in humans that intermittent hypoxia can increase both BP and endothelin-1, and that circulating levels of this powerful vasoconstrictor are reduced by CPAP treatment. 79, 80 Coagulopathy A hypercoagulable state is characterized by an imbalance between procoagulant and anticoagulant molecules occurring before the appearance of a thrombotic clinical event. This prothrombotic state, assessed by various parameters (platelet aggregability, haematocrit, fibrinogen, blood viscosity, thrombin/antithrombin III complex, fibrin D-dimer and von Willebrand factor antigen), is found more often in association with OSAS and seems to be mediated by comorbid HT. 81 This phenomenon partly explains the high prevalence of thrombotic cardiovascular events in apnoeic patients, especially when they also suffer from HT. Most of the studies carried out in the area show that the haemostasis and coagulation anomalies observed during OSAS are improved by nCPAP treatment. The hypercoagulable state, however, does not itself encourage an increase in BP readings.
OSAS behind HT: epidemiological data
The role of OSAS in the genesis of HT is now clearly established. Indeed, an increase in the relative risk of HT concomitant with OSAS has been shown in the general population. 13, 82 In the Sleep Heart Health Study, with an AHI 430/h, the relative risk was between 1.37 and 2.27 depending on the control variables. 13 The results of the Wisconsin Cohort Study are perhaps more conclusive still. 11, 12 In fact, in this study, the occurrence of HT was established through follow-up at 4 and 8 years, compared with the initial findings, in particular the polygraphic findings. 12 When the initial AHI was between 0.1 and 5, the relative risk of HT was 1.42; when the initial AHI was between 5 and 15, the relative risk was 2.03; and when initial AHI was more than or equal to 15, it was 2.89. All of these values were controlled for confounding factors such as the initial BP level, habitual anthropometric variables, alcohol consumption and smoking. In addition, prospective longitudinal evaluation supports the hypothesis that OSAS is a causal factor of HT.
12 This is what led to OSAS being recognized as a cause of HT, to be considered in any subject with abnormally high BP values. 83, 84 
HT and OSAS: clinical data
Obstructive sleep apnoea syndrome is at least three times more prevalent in hypertensive patients than in normotensive subjects. 85 OSAS is therefore accepted as a cause of HT by many authors and is also acknowledged as such in the European and the American recommendations on HT. 83, 84 If the data are precisely stratified depending on BMI, there is a significant positive 'dose-response' type relationship between AHI and BP. 11, 86, 87 This relationship is much clearer in subjects under 50-60 years of age than in older subjects. 86, 88 Haas et al. 88 found that OSAS is associated with systolic/diastolic HT in patients aged o60 years, but no association was found between OSAS severity and both isolated systolic HT in either age category and systolic/ diastolic HT in patients aged X60 years. This is partly explained by the difference in cardiovascular regulation in these two populations. We should also remember that the relationship between OSAS and mortality is present especially before the age of 60 years and then decreases with age. 32 In a case-control study (normotensives vs hypertensives), Drager et al. 89 showed that age, BMI, a family history of HT and being female were phenotypic characteristics associated with HT among 152 OSAS patients with similar disease severity.
Hypertension is widely unrecognized during OSAS. It should therefore be systematically investigated by means of clinical BP measurement which should respect the recommended measurement conditions. 86, 84 Over half of apnoeic patients are hypertensive but prevalence depends on several elements, including the method used to measure the BP. In a study including 59 subjects without cardiovascular history, without vasoactive treatment and not known to be hypertensive, HT was found in 42% of patients using the clinical measurement and 76% of patients using ABPM.
14 It is important to note that, in this same cohort, cardiovascular alterations partly linked to HT were found, such as reduced baroreflex sensitivity, increased thickness of the carotid wall (that is, common carotid intimamedia thickness X0.8 mm) and the presence of carotid atherosclerotic plaques. 14, 90 Other studies have analysed the relationship between OSAS and arterial anomalies. Among these, Protogerou et al. 91 recently showed that arterial stiffening and thickening are modulated by the severity of the OSAS, independently of age and cardiovascular risk factors.
Aside from its high prevalence, OSAS HT has several characteristics. It is not surprising that it is predominantly nocturnal given the fact that the apnoeas occur primarily during sleep at night. 14 However, many experimental and epidemiological studies have shown that HT also develops during the day in apnoeic patients. 12, 13, 92 One of the consequences of the nocturnal predominance of OSAS-related HT is the frequent presence of a non-dipper profile or an attenuated BP reduction in these subjects. 38, 39, 93, 94 The recent study by Hla et al. 94 showed that a dose-response increase in the development of systolic non-dipping BP as the severity of OSAS increased existed in a subsample of 328 subjects enrolled in the Wisconsin Sleep Cohort study. Another characteristic that is less well known but clearly proven is preferential elevation of the diastolic BP (DBP) during OSAS. 14, 95, 96 Predominantly, diastolic and even isolated diastolic HT is therefore frequent in apnoeic patients, especially when ABPM is used; it is of the order of 75%, and is all the more frequent if the OSAS is severe. 14 The principal mechanism behind the increased DBP in this disease is the increase in peripheral vascular resistance secondary to sympathetic hyperactivity.
The prevalence of OSAS is high in cases of refractory/resistant HT, the definition of which according to ESH-ESC guidelines is 'when a therapeutic plan that has included attention to lifestyle measures and the prescription of at least three drugs (including a diuretic) in adequate doses has failed to lower systolic BP (SBP) and DBP to goal'. 84 Several authors have shown that the prevalence of OSAS is around 75% in patients with refractory HT. 97, 98 Gonçalves et al. 98 found that OSAS was strongly and independently associated with resistant HT (odds ratio 4.8) in a case-control study carried out on 126 subjects. All of the data in the literature therefore enable us to pinpoint OSAS as one of the etiologies to be systematically investigated in cases of resistant HT. 84, 99 Interestingly, Lavie et al.
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found that uncontrolled hypertensive subjects had significantly higher AHI in a large cohort of 1485 OSAS patients. In a study carried out on 61 patients with resistant HT, Pratt-Ubunama et al. 101 showed a significant correlation between plasma aldosterone concentration and OSAS severity, suggesting that excess aldosterone may contribute to the severity of OSAS.
The HT found during OSAS is frequently associated with metabolic anomalies. This relationship is clearer if subjects are overweight or have abdominal obesity. This leads to a higher prevalence of metabolic syndrome in this population. Coughlin et al. 103 have shown that metabolic syndrome, as set out by the NCEP guidelines, 102 is 9.1 times more likely to be present in subjects with OSAS. Vgontzas et al. 104 have reported a close relationship between visceral obesity, insulin resistance and hyperleptinaemia in patients suffering from OSAS. In this context, it is interesting to note that insulin resistance and leptinaemia can be reduced by nCPAP. [105] [106] [107] The left ventricular hypertrophy seems to be more common in cases of OSAS, even after taking the BP into account. 108, 109 The frequency of the left ventricular hypertrophy increases as the severity of OSAS increases. 110 The greater prevalence of the left ventricular hypertrophy in apnoeic patients appears to be related to postload elevation during apnoea episodes and sympathetic hyperstimulation. 110 However, these data should be treated with caution because of the difficulty of obtaining a reliable measurement of the left ventricular mass in OSAS patients who are often overweight.
Methods of measuring BP in patients with OSAS
Blood pressure should be measured systematically in all apnoeic patients when OSAS has been diagnosed, but also during the patient's entire monitoring period, regardless of whether or not they are treated. As for the general population, the reference method for BP testing is clinical measurement. However, this method is imperfect due to the specific characteristics of the HT associated with OSAS, in particular, the fact that it is predominantly nocturnal. ABPM therefore seems to be the most informative BP measurement in apnoeic patients (Figure 3) . Furthermore, the latest European recommendations on HT treatment recommend that it be used when OSAS has been diagnosed. 84 ABPM enables masked HT to be diagnosed (that is, clinically normal BP but high BP when ABPM is used). This particular type of HT is frequently found with OSAS (in around 30% of cases) and is associated with greater cardiovascular effects than when OSAS patients have high clinical BP measurements but normal ABPM measurements. 39 Home BP measurement was not assessed in this indication. For the moment, it should therefore be used for OSAS patients, as for any other hypertensive patient.
The effect of OSAS treatment on BP
Treatment for OSAS combines lifestyle and diet measures (weight loss and a reduction in alcohol and tobacco consumption), drug restrictions (for example, avoidance of hypnotics) and specific therapies. In terms of specific therapies, nCPAP is the reference treatment, but there are also others, such as avoiding the supine position (lying on the back) when sleeping in the event of positional OSAS, using a mandibular advancement prosthesis (oral appliance) or, more rarely, surgery (in cases of facial dysmorphia).
The pathophysiological basis for the effect of OSAS treatment with nCPAP upon BP Nasal continuous positive airway pressure prevents respiratory events, restores normal quality sleep and causes daytime fatigue to disappear. By normalizing ventilation during sleep, it prevents the bursts of sympathetic activity present at the end of each respiratory event. Somers et al. 61 have also shown that nCPAP enables the mean sympathetic activity level during non-rapid-eye-movement sleep to be brought down to a level below that of when patients are awake, as is found in normal subjects. Treatment with nCPAP leads to a reduction in urinary catecholamine and sympathetic activity during waking and sleeping. 111 However, this reduction in sympathetic activity is not systematically associated with a significant fall in diurnal BP. Furthermore, plasma noradrenaline levels may not always be normalized with nCPAP treatment. 112 NO levels, abnormalities in venodilation or in NO-dependent vasodilation, C-reactive protein, interleukin-6, vasoactive hormones and baroreflex sensitivity return to normal under nCPAP. 67, 73, [113] [114] [115] [116] The effects of OSAS treatment with nCPAP upon BP readings The main aim of nCPAP is to reduce obstructive nocturnal events and consequently the diurnal fatigue that is often associated with them. In parallel with this beneficial effect, a potential reduction in BP during nCPAP treatment has also been researched for now 20 years 62 and has been studied by numerous teams. The results are sometimes divergent; some studies show that nCPAP has a beneficial effect, whereas others show that it is ineffective. However, no study has even shown that 12 nCPAP has a prohypertensive effect. Each study uses a different method with regard to the population studied (numbers, gender, BMI, presence of HT, antihypertensive treatment and so on), the degree of severity of the OSAS, the BP parameters analysed (SBP, DBP or mean BP), the techniques used to measure the BP (clinical, 24-h ABPM or Portapres continuous BP monitoring), the comparator used (absence, sham nCPAP or drug treatment) and the duration of the nCPAP treatment. Several studies have shown that nCPAP can reduce the BP of apnoeic patients, especially DBP and nocturnal BP. [117] [118] [119] However, the majority of these studies included less than 50 subjects and many of them were neither randomized nor controlled. The study with the largest patient population was completed by Bö rgel et al. 120 on 196 apnoeic subjects. In this non-randomized and noncontrolled study, 6 months of treatment (189 nCPAP and 7 bilevel positive airway pressure) significantly but weakly decreased clinical DBP only.
The year 2007 saw the first meta-analyses performed on the subject. In total, the three metaanalyses used 19 randomized controlled trials ( Table 1 ). The one by Haentjens et al. 121 looked at 12 studies versus placebo (sham nCPAP or antihypertensive treatment), including a total of 512 patients. Some of the studies analysed excluded hypertensive patients, whereas others only included hypertensive patients. Furthermore, the presence of an antihypertensive treatment was not constant and the duration of the nCPAP treatment was not specified. The main result of this meta-analysis was that the reduction in mean BP over 24 h with nCPAP is low (À1.69 mm Hg) but significant (Po0.001). This BP reduction is more marked if patients have severe OSAS and if they comply with their nCPAP treatment properly. Alajmi et al.
122 used 10 studies in their meta-analysis (N ¼ 587 patients), including seven that had been used by Haentjens et al. Two of the studies out of the 10 included patients with heart failure. Although the clinical SBP reduction with nCPAP was not significant, clinical DBP tended to be À1.52 mm Hg (P ¼ 0.06). When compliance with the nCPAP treatment was better, the SBP tended to fall, whereas the DBP remained unchanged. When only studies where the mean AHI was over 30/h were analysed, the DBP decreased significantly with nCPAP treatment (À2.03 mm Hg, P ¼ 0.05). When only studies excluding patients with heart failure were taken into account, the reduction in clinical BP with nCPAP treatment was not significant. Finally, the metaanalysis conducted by Bazzano et al.
123 used 16 placebo-controlled studies comparing the effect of nCPAP on BP over at least 2 weeks. Out of the 818 OSAS patients included, the mean BP reduction with active treatment versus placebo was À2.46 mm Hg (95% confidence interval (CI): À4.31 to À0.62) for SBP and À1.83 mm Hg (95% CI: À3.05 to À0.61) for DBP. The SBP and DBP decreases were identical for the day and night. The studies taken into account were different with regard to the BP parameters used (SBP, DBP or mean BP), the type of control treatment used (eight used sham nCPAP, four provided a pill and four provided usual care alone) and also the method of outcome measurement (ABPM or clinical BP). A significant BP reduction is associated with higher baseline BP levels, higher BMI and more severe OSAS. Out of the 19 studies (N ¼ 920 subjects) retained in the three meta-analyses, only 10 (N ¼ 436 subjects) showed that nCPAP had a statistically favourable impact on BP. Some studies have analysed the variations in dipper/non-dipper profiles with nCPAP treatment. Two authors found that the prevalence of nondipping decreased from approximately 50% before treatment to around 20% after 3 days to 4 months of nCPAP treatment. 117, 124 On the contrary, an increase in non-dipping after 4 weeks of nCPAP treatment was found by another author. 125 It is therefore difficult to conclude at this stage that nCPAP treatment has a potentially beneficial effect on the dipping/non-dipping status.
Results of studies published to date suggest, but do not definitively confirm, that nCPAP has a beneficial effect on BP in patients suffering from OSAS. The current data (studies and meta-analyses) give us an idea of the profile of apnoeic patients who seem to be able to benefit the most from treatment with nCPAP from a BP point of view (Table 2) . Such patients are hypertensive, especially if their BP figures are very high and if the HT is not treated or is refractory. In cases of refractory HT, it has been shown that not only a month, but just one night of nCPAP can significantly reduce nocturnal BP. 126, 127 Furthermore, nCPAP is more effective on BP if the OSAS is severe and if the nCPAP is well tolerated by the patient with compliance of at least 3 h per night. Nonetheless, a large-scale study with a rigorous methodology still needs to be carried out to gain a better appreciation of the effect that nCPAP has on BP in patients with OSAS.
The effects of OSAS treatment with an oral appliance upon BP values Few studies have addressed the effect of treatment with an oral appliance upon BP readings. In the study by Gotsopoulos et al., 128 carried out on 61 apnoeic subjects, the effects of the mandibular advancement splint were compared with a control oral appliance (that did not advance the mandible). The results are promising as DBP over 24 h decreased significantly (À1.8 mm Hg, Po0.001) with the active treatment, as did diurnal SBP and DBP (À3.3 mmHg, P ¼ 0.003; À3.4 mmHg, Po0.0001, respectively). Another crossover study showed that only nocturnal DBP decreased significantly (À2.2 mm Hg, Po0.01) with an oral appliance. 129 Other studies using this treatment for OSAS are clearly essential to draw a conclusion on whether or not it has a beneficial effect on BP.
Drug treatment for HT during OSAS
Few studies have investigated the impact of pharmacological treatment for HT associated with OSAS. A comparative evaluation of various drugs has led to the recommendation that b-blockers be used. 130 However, other studies are required, in particular taking into account the HT stage, BP response with nCPAP treatment and associated cardiovascular morbidity. Antihypertensives do not seem to have any effect on respiratory parameters during OSAS. No significant change to AHI was found with a-methyldopa, b-blockers, calcium-channel antagonists or ACE inhibitors. 131, 132 Current perspectives (1) It has been clearly established that OSAS encourages the development of HT, especially in obese patients who are under 60 years of age. The characteristics of OSAS-related HT are better known, as are the pathophysiological mechanisms. However, this HT remains under-diagnosed. It is therefore essential to measure the clinical BP, according to the recommendations, of all patients suffering from OSAS, and even, in certain cases, to use ABPM to investigate masked HT and non-dipping status. (2) The cardiovascular prognosis of apnoeic patients is worse than that for the general population. It is therefore imperative that we assess the cardiovascular risk using the equations at our disposal, but also taking into account potential lesions in the target organs (that is, microalbuminuria, carotid wall lesions and the left ventricular diastolic dysfunction). (3) Nasal continuous positive airway pressure treatment seems to be effective in a select group of OSAS patients. Before reaching a definitive conclusion on the positive effect that this treatment has on BP, a large randomized and controlled study, ideally using ABPM, needs to be completed.
Conclusion
The causal link between OSAS and HT is now clearly established. The 'dose-effect' type relationship connecting the two diseases persists after controlling for confounding factors (sex, age, BMI and smoking). HT should be investigated in all 
